Navigation Links
Pasteuria Bioscience Receives EPA Registration for Nematode Control
Date:6/8/2009

ALACHUA, Fla., June 8 /PRNewswire/ -- Pasteuria Bioscience announced that it has received registration from the United States Environmental Protection Agency (EPA) for Pasteuria usgae. This is a critical step towards the commercial use of Pasteuria spp., a natural bacteria prevalent in soil that have long been recognized as promising biological control agents for plant-parasitic nematodes.

"We're very pleased to receive this EPA registration," said David Duncan, Ph.D., chief executive officer for Pasteuria Bioscience. "It confirms Pasteuria usgae as a safe, effective and an environmentally-friendly agent for sting nematode control."

Pasteuria spp. was first discovered over 50 years ago and identified as an effective agent for nematode control. Scientists have considered Pasteuria to be among the most promising biological agents for control of plant-parasitic nematodes, but until recently, no one was able to grow Pasteuria outside of the body of a nematode. Thus, it could not be produced cost-effectively on a commercial scale. Pasteuria Bioscience has developed a revolutionary new technology that allows the rapid and cost-effective growth of multiple strains of Pasteuria manufactured through traditional fermentation methods.

The Society of Nematology and other organizations estimate global crop losses due to nematodes at $100 billion annually making it agriculture's largest unmet pest control need. With current nematicides being voluntarily removed from the market due to safety and environmental concerns, few nematicide options exist to meet this demand. The registration of Pasteuria spp. is important in offering environmentally safe, cost-effective and reliable nematode control products helping to fill the niches that will be vacated by current nematicides.

With a robust pipeline of product candidates based on Pasteuria technology, this registration is the first of many to come. P. usgae is a highly efficacious biological nematicide and will be targeted for control of sting nematode in the golf, sports turf and landscape markets.

"This first step is important for Pasteuria Bioscience and serves as validation of the credibility of Pasteuria-derived products. We're confident about the future of this technology as an important tool to help growers control nematodes in a variety of crops and regions of world," said Duncan.

About Pasteuria Bioscience

Pasteuria Bioscience, Inc. was founded in 2003 in the University of Florida's Sid Martin Biotechnology Incubator. The company was developed out of Entomos, Inc., to commercialize its revolutionary technology for production of nematode control products based on Pasteuria technology.

Pasteuria Bioscience is developing products based on Pasteuria spp. to treat major nematode pests in most agricultural crops. Its first product will provide sting nematode control for the golf and sports turf markets. Subsequent products will offer nematode control in agronomic crops such as soybean and cotton, in specialty crops such as strawberry and banana; and in vegetables.

Pasteuria Bioscience continues to build its pipeline of products and its intellectual property portfolio through a vigorous development program.

For more information, visit the Pasteuria Bioscience web site at http://www.pasteuriabio.com.


'/>"/>
SOURCE Pasteuria Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pasteuria Bioscience Taps New CEO David N. Duncan
2. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
3. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
4. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
5. Regado Biosciences Establishes Medical Advisory Board
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
7. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
8. EUCODIS Bioscience Signs Research Agreement With Genencor
9. Universite de Montreal and Validapro Biosciences Inc. have Signed an Agreement-in-Principle
10. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
11. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... 2016  Silk Therapeutics, Inc., today announced the closing of ... now raised a total of $10.25 million in Series A ... Series A2 round was led by existing investor The Kraft ... from new investors Lear Corporation and Highland Consumer Partners, as ... ; Richard Sackler , MD, with Summer Road, LLC; ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):